20.09.2018 • News

Venator to Shut Pori Pigment Plant

Venator to Shut Pori Pigment Plant
Venator to Shut Pori Pigment Plant

Venator, currently in talks with Tronox to buy the Ashtabula TiO2 plant in the US, said it will permanently shut its pigment plant in Pori, Finland. The 130,000 t/y plant, at the time owned by Venator’s predecessor Huntsman, was damaged after a fire on Jan. 30, 2017.

The closure, said Venator, was down to escalating costs and the extended time now needed to reconstruct the facility. Instead, the company will transfer roughly 45,000 t/y of the specialty and differentiated grades produced at Pori to other sites within its network.

During the transition, which is expected to last through 2021, Pori will continue to operate at a rate of approximately 25,000 tonnes/year, or about 20% of the site’s capacity.

Simon Turner, Venator’s president and CEO, said the decision to close was made following an “intense” review. “Closing the site is the best decision for the long-term success of our business, as we expect to restore the majority of our specialty and differentiated earnings formerly generated by Pori, using our existing facilities. We also believe doing so will preserve our financial flexibility and improve our ability to deliver free cash flow throughout the cycle.”

In total, Venator will spend about $150 million to upgrade certain of its other facilities, which it said will become more efficient with greater flexibility. The company did not disclose which plants will be upgraded.

 

Interview

Leading Transformation
The Path to Sustainable Growth

Leading Transformation

As Executive Vice President of International Chemicals since early 2024, Antje Gerber has been steering Sasol through a pivotal reset—focused on resilience, innovation, and bold sustainability goals.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read